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Background: The application of vaccine adjuvants has been vigorously studied for a diverse range of diseases in
order to improve immune responses and reduce toxicity. However, most adjuvants have limited uses in clinical
practice due to their toxicity.
Methods: Therefore, to reduce health risks associated with the use of such adjuvants, we developed an advanced
non-toxic adjuvant utilizing biodegradable chitosan hydrogel (CH-HG) containing ovalbumin (OVA) and
granulocyte-macrophage colony-stimulating factor (GM-CSF) as a local antigen delivery system.
Results: After subcutaneous injection into mice, OVA/GM-CSF-loaded CH-HG demonstrated improved safety and
enhanced OVA-specific antibody production compared to oil-based adjuvants such as Complete Freund’s adjuvant
(CFA) or Incomplete Freund’s adjuvant (IFA). Moreover, CH-HG system-mediated immune responses was characterized by
increased number of OVA-specific CD4+ and CD8+ INF-γ+ T cells, leading to enhanced humoral and cellular immunity.
Conclusions: In this study, the improved safety and enhanced immune response characteristics of our novel adjuvant
system suggest the possibility of the extended use of adjuvants in clinical practice with reduced apprehension about
toxic side effects.
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Vaccine adjuvants have been extensively studied in order
to enhance their safety and improve the immune re-
sponses elicited by the accompanying antigen for im-
munotherapy [1-3]. However, conventional adjuvants
evoke serious side effects due their toxicity [4]. This
has limited their use in clinical trials in recent years
and poses as a serious hurdle to effective adjuvant-based
immunotherapy, resulting in side effects such as boil
and pyrexia occurring in clinical trials. Mineral oil-based
media, Complete Freund’s adjuvant (CFA) and Incomplete* Correspondence: hanhd@kku.ac.kr; twkim0421@korea.ac.kr
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unless otherwise stated.Freund’s adjuvant (IFA) [5,6], are available as commercial-
ized products and are potent adjuvants commonly used in
animal research, as they can augment both humoral and
cellular immune responses to a wide range of antigens.
However, they are toxic to human subjects, and their use
in animals are now also discouraged or banned by
many institutional animal ethics committees due to
their noxious side effects [4]. These limitations enforce
the need for novel and improved adjuvant systems to
replace the existing ones.
Here, we have developed an improved chitosan hydro-
gel (CH-HG) system as a vaccine adjuvant to enhance
induced immune responses and reduce toxicity [7,8].
Chitosan is particularly attractive for clinical and bio-
logical applications due to its low toxicity, low immuno-
genicity, biocompatibility, and biodegradability [8,9]. In
addition, CH-HG displays a liquid-solid phase transition. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be injected at the diseased site without a requirement
for surgical procedure. Therefore, CH-HG may lead to
enhanced safety and immune responses at disease sites.
Moreover, CH-HG can be gradually degraded by en-
zymes in the body after the antigen has been completely
released.
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) has been used as a vaccine adjuvant, which
stimulates macrophage differentiation and proliferation,
and to activate antigen presenting cells (APCs) such as
dendritic cells (DCs) or macrophages. These qualities
make GM-CSF important and relevant to developing vac-
cine therapies [10-12]. GM-CSF can augment the primary
immune response of murine spleen cells to sheep red
blood cells and increase interleukin-1 secretion [13]. In
addition, GM-CSF can increase the immunogenicity of tu-
mors in animal models and stimulate both humoral and
cellular immune responses, thus serving as an effective ad-
juvant for DNA or peptide based vaccines [14,15]. This in-
creased immune response is presumed to be a result of
the GM-CSF-mediated increase in maturation and func-
tion of APCs [16]. Further studies, using microspheres of
encapsulated GM-CSF mixed with irradiated tumor cells
that were injected subcutaneously also demonstrated in-
creased tumor immunogenicity [17]. These studies moti-
vated us to ask whether GM-CSF function could be
improved in prolonged immune responses at a local adju-
vant site. Here, we present a novel immunization strategy
using CH-HG-loaded GM-CSF/OVA as an adjuvant
system to increase immunogenicity in both humoral and
cellular immune responses in a mouse model as a proof-
of-concept, and in order to approach a clinically relevant
study of GM-CSF in CH-HG as an enhanced adjuvant
for vaccination that evokes an improved immune re-




Female C57BL/6 mice (6 weeks old, 20 g) were pur-
chased from Daehan Biolink (Chungbuk, Korea) and
maintained under a protocol approved by the Korea
University Institutional Animal Care and Use Committee
(KUIACUC-2013-210). All procedures were performed
in accordance with recommendations for the proper ani-
mal care and use.
Preparation of OVA and GM-CSF-loaded CH-HG
We have previously reported the physical characteristics
of CH-HG as an in vitro or in vivo depot system after
subcutaneous (SC) injection [8,9]. We prepared CH-HG
containing OVA and/or GM-CSF with mild modification
made to our previously reported method. Briefly, chitosansolution (medium molecular weight of 161 kDa, viscosity
of 200,000 cps and a degree of deacetylation of 80%) was
obtained by dissolving 40 mg of chitosan in 1.8 ml of 0.1
M HCl solution. Glycerol 2-phosphate disodium salt hy-
drate (β-GP) solution containing 50 μg of OVA and/or 50
ng of GM-CSF was prepared by dissolving 0.2 g of β-GP
and predetermined amount of OVA or GM-CSF in 0.2 ml
of distilled water. The CH solution was cooled to 4°C and
continuously stirred while adding 0.2 ml of mixed solution
was added. The final product is successfully formed hydro-
gel at body temperature and physiological pH in vivo after
subcutaneous (SC) injection into mice. Notably, the mice
did not suffer severe side effects, including pus formation
or inflammation, and maintained a healthy appearance
after CH-HG implantation.
Safety test of CH-HG in mice after SC injection
To confirm the safety of adjuvants, 50 μl of CH-HG,
Complete Freund’s adjuvant (CFA), or Incomplete Freund’s
adjuvant (IFA) were injected subcutaneously into mice. The
external morphologies of the adjuvants were monitored in
the mice, and the hydrogel volume was measured using cal-
ipers for 14 days. After 14 days from initial administration,
we measured body weights to evaluate the toxicity of each
adjuvant.
Immune response against CH-HG containing OVA + GM-CSF
Fifty microliters of CH-HG, CFA, and IFA containing
OVA +GM-CSF were injected subcutaneously into mice,
and the adjuvants were boosted at 7 days using the same
injection volume. The IgG, IgG1, and IgG2a levels in
serum were measured by ELISA 3 weeks after the first
immunization. Briefly, the presence of OVA-specific anti-
bodies in the sera from CH-HG mediated immunization
of C57BL/6 mice (five per group) was determined by
ELISA using microwell plates coated with OVA protein.
Purified OVA protein was diluted to 0.5 μg/ml in PBS buf-
fer (pH 7.4), and 50 μl of that solution was then added to
each well of 96-well microtiter plates. Purified OVA pro-
tein was used as a negative control. The plates were incu-
bated overnight at 37°C, followed by three washes with
300 μl of PBS. After washing, 200 μl of blocking solution
(1% skim milk) was incubated at 37°C for 1 hr, and then
the plates were washed three additional times using PBS
containing 0.05% Tween20 (PBS-T). Serial dilutions of the
tested sera were made (0.1 ml/well), and the plates were
incubated for 1 hr at 37°C. The plates were washed with
PBS-T and incubated with 0.1 ml of alkaline phosphatase-
conjugated rabbit anti-mouse antibodies (Zymed) per well
for 1 hr at 37°C. The plates were again washed with PBS-
T and incubated with alkaline phosphatase substrate (100
μl/well, Sigma) according to the manufacturer’s instruc-
tions for 1 hr at 37°C. Plates were read on a MicroElisa
reader at a wavelength of 650 nm (Additional file 1).
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To assess OVA specific immune responses, we immu-
nized mice with 50 μl of one of five different solutions;
1) 50 μg of OVA solution, 2) 50 μg of OVA solution with
GM-CSF, 3) CH-HG containing 50 μg of OVA, 4) CH-
HG containing 50 μg of OVA +50 ng of GM-CSF, or 5)
IFA containing 50 μg of OVA +50 ng of GM-CSF. Sple-
nocytes were harvested from the immunized mice (five
per group) for 2 weeks after the first immunization.
Prior to intracellular cytokine staining, 5 × 106 pooled
splenocytes from each immunization group were incu-
bated overnight with 1 μg/ml OVA peptide containing
MHC class I epitope (aa 257-264) or MHC class II epi-
tope (aa 323-339) to detect OVA-specific CD4+ and
CD8+ T cell precursors. Intracellular IFN-γ and IL4
staining, as well as flow cytometric analysis were per-
formed using a Becton-Dickinson FACScan with CELL-
Quest software (Becton Dickinson Immunocytometry
Systems, Mountain View, CA). The number of OVA-
specific INF-γ or IL4 secreting CD4+ T cells and INF-γ
secreting CD8+ T cells were assessed by intracellular
cytokine staining and FACScan analysis.
Statistical analysis
Differences in continuous variables were analyzed by
Student’s t-test for comparing two groups and ANOVA was
performed to compare differences between multiple groups.
For values that were not normally distributed, the Mann-
Whitney rank sum test was used. The statistical packageFigure 1 Safety of CH-HG compared to that of commercial adjuvants,
the injection site in mice. (B) Change in volume of injected adjuvants after
means ± S.D. (n = 5).for the Social Sciences (SPSS, Inc.) was used for all statis-
tical analyses. A p value of <0.05 was considered statistically
significant.
Results
CH-HG safety after SC injection in mice
We first confirmed hydrogel formation after SC injection
of CH into mice (Figure 1A). The CH solution displayed a
liquid-solid phase transition in a temperature-dependent
manner and formed an endothermic hydrogel at the injec-
tion site. Furthermore, we noted no pus, discharge, or scab
formation at the injection site of CH-HG solutions, indi-
cating improved safety compared to commercially avail-
able CFA or IFA (Figure 1A). Moreover, CH-HG was not
present at the injection site 2 weeks after injection, sug-
gesting increased biodegradation compared to CFA and
IFA (Figure 1B). We also checked the body weights of
mice for 2 weeks after SC injection of CH-HG to evaluate
adjuvant toxicity (Figure 1C). While CFA and IFA injected
groups weighted less, the CH-HG injected group did not
weigh significantly different than the control group, sug-
gesting that the CH-HG system displayed enhanced safety
at the in injection site. Therefore, CH-HG may be useful
as a safer adjuvant system in mice.
CH-HG containing OVA and GM-CSF induced titers of OVA
specific IgG
To determine the effectiveness of CH-HG in inducing
an immune response, we assessed the humoral immunein mice after subcutaneous administration. (A) Morphology of
14 days. (C) Body weight of mice. The data are presented as the
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Two weeks after the last SC injection of CH-HG/OVA
into mice, OVA specific IgG expression was significantly
induced, and measured 10-fold higher than that in mice
immunized with soluble OVA alone (p <0.001) (Figure 2A).
Additionally, OVA specific IgG progressively increased
rising to a 107-fold increase in expression 5 weeks after
the last immunization (Additional file 2: Figure S1). Based
on the immune response data for CH-HG/OVA, we next
tested immune responses for CH-HG/OVA with 50 ng of
GM-CSF (CH-HG/OVA + GM-CSF), which further in-
creased the IgG titer (103-fold increase) compared to
the CH-HG/OVA without GM-CSF (p <0.001). We
therefore chose CH-HG/OVA + GM-CSF for all subse-
quent experiments (Figure 2A). In addition, there were
higher titers of OVA-specific IgG1 than of IgG2a in
serum from mice immunized with CH-HG/OVA +
GM-CSF (Figure 2B). These data demonstrate that
immunization with CH-HG/OVA+GM-CSF significantly
enhances OVA-specific humoral immune response (IgG1),
and the CH-HG induced immune response would be
strongly dependent on the Th2 type immune response.
CH-HG/OVA + GM-CSF induction of OVA-specific IgG
compared to CFA and IFA
Next, we checked whether CH-HG could increase OVA
specific IgG expression compared to commercialized
CFA or IFA. We first measured OVA specific IgG fromFigure 2 OVA-specific immune responses in mice immunized with 50
containing 50 μg of OVA and 50 ng of GM-CSF. Sera were collected fro
and were used to characterize OVA-specific antibodies. Mice received an im
Seven days after immunization, experimental groups were boosted. (A) Tite
lular immune response. The data are presented as the means ± S.D. (n = 5),the serum of mice immunized with CH-HG/OVA +
GM-CSF, CFA/OVA+GM-CSF, or IFA/OVA+GM-CSF
(Figure 3A). Mice immunized with CH-HG/OVA+GM-
CSF generated significantly higher titers of OVA-specific
antibody responses compared to mice immunized with
CFA/OVA+GM-CSF or IFA/OVA+GM-CSF (p <0.01).
Furthermore, the sera of mice immunized with CH-HG/
OVA+GM-CSF had significantly higher titers of OVA-
specific IgG1 antibodies compared to mice immunized
with CFA/OVA + GM-CSF or IFA/OVA + GM-CSF
(Figure 3B). These data indicate that immunization
with CH-HG/OVA + GM-CSF elicits a stronger OVA-
specific humoral immune response, providing a potential
alternative in clinical practice to existing commercially
available adjuvants such as CFA or IFA. However, the
IgG2a titers were similar between all groups of mice
(Figure 3C), which suggests that CH-HG/OVA+GM-CSF
may not contribute the IgG2 mediated immune responses.
CH-HG/OVA+GM-CSF generated an enhanced OVA-specific
cellular immune response
T cell mediated immunity is important for controlling
tumor cells and intracellular infections caused by bacteria
or viruses. For a quantitative characterization of OVA-
specific CD4+ T cell-mediated immune responses, we
performed flow cytometry analysis with or without the
MHC class II-restricted peptide OVA323-339 (ISQAV
HAAHAEINEAGR). As shown in Figure 4A and 4B, theμg of OVA solution, CH-HG containing 50 μg of OVA, and CH-HG
m immunized mice (3 per group) 2 weeks after the last immunization
munization with 50 μg of OVA per mouse via subcutaneous injection.
rs of OVA specific IgG. (B) Titers of OVA specific IgG for humoral or cel-
(*p <0.001, (**p <0.002).
Figure 3 OVA-specific immune responses in mice immunized with various adjuvants with or without GM-CSF. Sera were collected from
adjuvant-immunized mice (5 per group) 2 weeks after the last immunization and were used to characterize OVA-specific antibodies. Mice received
an immunization with 50 μg of OVA and 50 ng of GM-CSF via subcutaneous injection. Seven days after immunization, experimental groups were
boosted. (A) Titers of OVA-specific IgG in mice immunized with various adjuvants. (B) Titers of OVA-specific IgG1 in mice immunized with various
adjuvants. (C) Titers of OVA-specific IgG2a in mice immunized with various adjuvants. The data are presented as means ± S.D. (n = 5), (*p <0.01).
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T cells in the splenocytes of CH-HG/OVA+GM-CSF
immunized mice were significantly increased compared
to that of mice immunized with OVA or CH-HG/OVA
(p <0.001). We further measured CD8+ T cell immune re-
sponses by performing intracellular cytokine staining with
or without MHC class I-restricted peptide OVA257-264Figure 4 CH-HG/OVA + GM-CSF immunization generated enhanced O
control or CH-HG/OVA. C57BL/6 mice (5 per group) were immunized wit
were assessed in the immunized mice. (B) The bar graph depicts the numb
(C) The bar graph depicts the number of IFN-γ producing OVA-specific CD8+
with OVA, CH-HG/OVA or CH-HG/OVA + GM-CSF. The data are presented as m(SIINFEKL). As shown in Figure 4C, the numbers of
OVA-specific CD8+ T cells in splenocytes of mice immu-
nized with CH-HG/OVA+GM-CSF were higher than
those of the other groups (p <0.001). Collectively, these
data demonstrate that immunization with CH-HG/OVA
+GM-CSF adjuvant could elicit antigen-specific cellular
immune responses.VA-specific CD4+ and CD8+ T cell immune responses compared to
h CH-OVA/GM-CSF. (A) OVA-specific CD4+ T cell immune responses
er of OVA-specific IL4-secreting CD4+ T cells per 3 × 105 splenocytes.
T cell precursors per 3 × 105 splenocytes from mice after immunization
eans ± S.D. (n = 5), (*p <0.001).
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Adjuvant-based vaccination in immunotherapy is highly
effective, but it is associated with inherent safety and
toxicity problems that need to be overcome before use
in clinical settings [3,4]. We demonstrate here that a
novel CH-HG based adjuvant system loaded with GM-
CSF, a broad immune-modulating cytokine, led to potent
both humoral and cellular immune responses without
severe side effects. This approach has broad utility for
adjuvant mediated therapeutic materials as well as other
immunotherapy applications.
Several synthetic biomaterials have been proposed as
adjuvants for effective antigen delivery. These include
microparticles [18], nanofibers [19], metal-based parti-
cles [20], and emulsions [21]. Although many types of
compounds can be potentially used as delivery agents,
their safety and evoked immune responses cause concerns.
The development of adjuvant-based vaccination for im-
munotherapy, therefore, requires clinically suitable, safe,
and effective delivery systems.
Therapeutic materials packaged into CH-HG may pro-
vide a clinically viable approach for the development of
a vaccine related immunotherapy. The biocompatibility
and biodegradability of these systems are key parameters
for medical and pharmaceutical applications [9]. Here,
we demonstrate that a novel hydrogel-based adjuvant
system loaded with OVA and GM-CSF led to potent im-
mune responses in mice. This study implements a novel
adjuvant with improved safety and reduced toxicity. In
addition, the CH-HG system allows for the co-delivery
of therapeutic materials, such as an antigen, which could
further enhance the antigen specific immune response
without increasing toxicity. Injection of CH-HG is
simple because CH-HG is a liquid phase at room
temperature and therefore, does not require surgery
for insertion at the site of the disease, which would dis-
rupt the disease environment. Moreover, the biodeg-
radation rate of injected hydrogel can be controlled by
modifying the injected volume. In this study, we
injected 50 μl of chitosan solution, which degrades in
approximately 2 weeks, suggesting that this amount
can be used for repeated injections. This local depot
system may be attractive for many biomedical applica-
tions, including administration of anesthetic agents
after surgery and treatment of certain skin, breast, or
neck cancers. Such an approach may also be useful for
adjuvant therapy, or as a local treatment for chronic
periodontitis. Although the CH-HG mediated adjuvant
platform can be useful for diseases associated with the
immune system and with the intent to enhance im-
mune response, additional possibilities of optimized
loading for effective cytokine or immune modulator
using the CH-HG platform may be explored and devel-
oped for research purposes.Conclusion
In summary, we have developed a novel adjuvant system
that yields high immune responses without negative side
effects at the local site of interest due to matrix toxicity.
Our data demonstrate that CH-HG based local antigen
delivery can invoke antigen specific CD8+ T cell immun-
ity. Such CH-HG based adjuvant strategies may have
broad potential as antigen delivery platforms in human
disease and represent an opportunity for further devel-
opment of vaccine based immunotherapeutics.
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